Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer

ABSTRACT: To determine the efficacy (as measured by progression-free survival [PFS] rate at 8 weeks) of regorafenib in subjects with metastatic colorectal cancer (CRC) whose disease is refractory to standard therapies and who were never exposed to antiangiogenic therapy.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2191654 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR